Follow us for updates
© 2021
Read the Story →

Study Shows Higher Risk of Bell's Palsy After Sinovac Dose

The benefits of vaccine outweighs the risk.
by Reuters
Just now
Photo/s: Jerome Ascano

Risk of Bell's Palsy, a type of facial paralysis, is higher after the first dose of Sinovac Biotech Ltd's COVID-19 vaccine CoronaVac, according to a study published in The Lancet Infectious Diseases journal.

"The beneficial and protective effects of the inactivated COVID-19 vaccine far outweigh the risk of this generally self-limiting adverse event," the study mentioned.

The study conducted in more than 451,000 individuals showed 28 clinically confirmed cases of Bell's Palsy following CoronaVac, compared to 16 cases following Pfizer/BioNtech's vaccine.

"Our findings suggest an overall increased risk of Bell's Palsy after CoronaVac vaccination," according to the study.

The study performed in Hong Kong assessed the risk of the adverse event within 42 days following vaccination.

Sinovac did not immediately respond to a request for a comment.

More stories on Sinovac

Continue reading below ↓
Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.